The US company's modifier gene therapy platform has the potential to treat multiple retinal diseases with one mutation-agnostic drug. Ocugen's novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, retinitis pigmentosa, dry age-related macular degeneration and diabetic retinopathy.

Ocugen is also co-developing Bharat Biotech’s Covaxin vaccine candidate for COVID-19 in the US and Canadian markets.